Quality of Life Research

, Volume 5, Issue 1, pp 15–19

A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: The MRC/EORTC QLQ-LEU

  • M. Watson
  • R. Zittoun
  • E. Hall
  • G. Solbu
  • K. Wheatley
Research Papers

Abstract

We describe the psychometric analysis of a supplementary quality of life measure (MRC/EORTC QLQ-LEU) for evaluating long term sequelae of leukaemia treatments. The questionnaire under development was administered to 388 patients entered into the EORTC-GIMEMA AML 8A and the MRC AML10 clinical trials who were in complete remission for at least one year after completion of treatment on these trials. Results indicated a measure which is useful in evaluating the long-term effects of treatment in relation to chronic graft-vs-host disease and infection susceptibility. The performance of this measure in terms of its sensitivity and specificity between treatment arms was established by comparisons between the three treatment modalities in the above-mentioned trials and is the subject of further investigation. The new Leukaemia Module can be recommended for use alongside generic QOL instruments as a measure of long-term quality of life in leukaemia trials.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: Quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.Google Scholar
  2. 2.
    Ringdal GI, Ringdal K. Testing the EORTC Quality of Life questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 1993; 2: 129–140.Google Scholar
  3. 3.
    Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire. J Clin Oncol 1995; 13: 1249–1254.Google Scholar
  4. 4.
    Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30: 635–642.Google Scholar
  5. 5.
    For the EORTC QL Study Group. Guidelines for module development and refinement.Google Scholar
  6. 6.
    Harris CW. On factors and factor scores. Psychometrika 1967; 32: 363–379.Google Scholar
  7. 7.
    Child D. The Essentials of Factor Analysis. Holt, Rinehart & Winston Ltd, UK, 1970.Google Scholar
  8. 8.
    Cary, NC. SAS/STAT User's Guide; Ver 6, 4th Ed, Vol 1. SAS Institute Inc, 1989.Google Scholar
  9. 9.
    Zittoun RA. Mandelli F, Willemze R, et al. Autologous or allogenic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Eng J Med 1995; 332: 217–223.Google Scholar
  10. 10.
    Lesko LM. Psychiatric aspects of bone marrow transplantation: Part II: Life beyond transplant. Psycho Oncol 1993; 2: 185–194.Google Scholar
  11. 11.
    Andrykowski MA, Henslee PJ, Farrall MG. Physical and psychosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transpl 1989; 4: 75–81.Google Scholar
  12. 12.
    Appelbaum FR, Dahlberg S, Thomas D, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 1984; 101: 581–588.Google Scholar

Copyright information

© Rapid Science Publishers 1996

Authors and Affiliations

  • M. Watson
    • 1
    • 2
  • R. Zittoun
    • 4
  • E. Hall
    • 3
  • G. Solbu
    • 5
  • K. Wheatley
    • 3
  1. 1.The Royal Marsden NHS TrustUK
  2. 2.Institute of Cancer ResearchUK
  3. 3.Clinical Trial Service UnitOxfordUK
  4. 4.Department of HaematologyParisFrance
  5. 5.EORTC Data CentreBrusselsBelgium

Personalised recommendations